Howson Joanna M M, Barratt Bryan J, Todd John A, Cordell Heather J
Juvenile Diabetes Research Foundation/Wellcome Trust Diabetes and Inflammation Laboratory, Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, UK.
Genet Epidemiol. 2005 Jul;29(1):51-67. doi: 10.1002/gepi.20077.
We compared different ascertainment schemes for genetic association analysis: affected sib-pairs (ASPs), case-parent trios, and unrelated cases and controls. We found, with empirical type 1 diabetes data at four known disease loci, that studies based on case-parent trios and on unmatched cases and controls often gave higher odds ratio estimates and stronger significance test values than ASP designs. We used simulations and a simplified disease model involving two interacting loci, one of large effect and one smaller, to examine interaction models that could cause such an effect. The different ascertainment schemes were compared for power to detect an effect when only the locus of smaller effect was genotyped. ASPs showed the greatest power for association testing under most models of interaction except under additive and certain epistatic crossover models, for which case/controls and case-parent trios did better. All ascertainment schemes gave an unbiased estimation of log genotype relative risks (GRRs) under a multiplicative model. Under nonmultiplicative interactions, GRRs at the minor locus as estimated from ASPs could be biased upwards or downwards, resulting in either an increase or decrease in power compared to the case/control or trio design. For the four known type 1 diabetes loci, we observed decreased risks with ASPs, which could be due to additive interactions with the remaining susceptibility loci. Thus, the optimal ascertainment strategy in genetic association studies depends on the unknown underlying multilocus genetic model, and on whether the goal of the study is to detect an effect or to accurately estimate the resulting disease risks.
患病同胞对(ASP)、病例-父母三联体以及无关病例与对照。利用四个已知疾病位点的1型糖尿病实证数据,我们发现,基于病例-父母三联体以及未匹配病例与对照的研究,往往比ASP设计给出更高的优势比估计值和更强的显著性检验值。我们使用模拟以及一个涉及两个相互作用位点(一个效应大,一个效应小)的简化疾病模型,来研究可能导致这种效应的相互作用模型。当仅对效应较小的位点进行基因分型时,比较了不同确定方案检测效应的效能。除了加性模型和某些上位性交叉模型(在这些模型中病例/对照和病例-父母三联体表现更好)外,在大多数相互作用模型下,ASP在关联检验中显示出最大效能。在乘法模型下,所有确定方案对对数基因型相对风险(GRR)的估计都是无偏的。在非乘法相互作用下,从ASP估计的次要位点的GRR可能会向上或向下偏倚,与病例/对照或三联体设计相比,导致效能增加或降低。对于四个已知的1型糖尿病位点,我们观察到ASP的风险降低,这可能是由于与其余易感位点的加性相互作用。因此,遗传关联研究中的最佳确定策略取决于未知的潜在多位点遗传模型,以及研究的目标是检测效应还是准确估计由此产生的疾病风险。